BioSpace News Archive

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on its corporate activities and product pipeline.

MediciNova, Inc. announced an abstract entitled “Improvement of Serum Lipid Panel by Tipelukast in Type 2 Diabetes and NAFLD Patients” has been accepted and selected for poster presentation at the International Diabetes Federation 2022 Congress to be held December 5 - 8, 2022.

REVA Medical, LLC., a leader in bioresorbable polymer technologies for vascular applications, is pleased to announce the closing of a $45 million Series B equity financing.

BioAtla, Inc. (Nasdaq: BCAB), today announced its financial results for the second quarter ended June 30, 2022, and provided an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in NSCLC as well as an operational update on its ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071) addressing multiple tumor types.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus and other viral diseases, announced financial results and recent highlights for the second quarter ended June 30, 2022.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today provided a corporate update and reported financial results for the quarter ended June 30, 2022.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported financial results for the second quarter of 2022.

Metacrine, Inc., a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal diseases, reported its second-quarter 2022 financial results.

ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it has received 510(k) clearance for its ClearPoint Maestro™ Brain Model.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.